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Conventional medical treatments of Parkinson’s disease (PD) are effective on motor disturbances but may have little impact on
nonmotor symptoms, especially psychiatric ones. Thus, even when motor symptomatology improves, patients might experience
deterioration in their quality of life. We have shown that 3 years of active theatre is a valid complementary intervention for PD as
it significantly improves the well-being of patients in comparison to patients undergoing conventional physiotherapy. Our aim was
to replicate these findings while improving the efficacy of the treatment. We ran a single-blinded pilot study lasting 15 months on
24 subjects with moderate idiopathic PD. 12 were assigned to a theatre program in which patients underwent “emotional” training.
The other 12 underwent group physiotherapy. Patients were evaluated at the beginning and at the end of their treatments, using a
battery of eight clinical and five neuropsychological scales. We found that the emotional theatre training improved the emotional
well-being of patients, whereas physiotherapy did not. Interestingly, neither of the groups showed improvements in either motor
symptoms or cognitive abilities tested by the neuropsychological battery. We confirmed that theatre therapy might be helpful in
improving emotional well-being in PD.
1. Introduction
Parkinson’s disease is a progressive neurodegenerative dis-
ease that causes motor disturbances (e.g., slowness, rigidity,
tremor, and disorders of gait and balance) and nonmotor dis-
turbances such as neuropsychiatric symptoms (e.g., depres-
sion, anxiety, obsessive-compulsive disorders, and cognitive
impairments) and autonomic dysfunction (e.g., decreased
control of urinary bladder and sexual dysfunctions) [1].
Consequently, the general health and the social lives of
patients can be deeply impaired [2].
Standardmedical treatments based on the administration
of dopaminergic drugs [3, 4] allow optimal control of the
motor symptoms, especially in the initial stages of PD;
however, with chronic treatment, motor and behavioral com-
plications partly unmasked by dopaminergic medications
may develop [5]. Moreover, dopaminergic drugs are not
often fully effective in controlling the full clinical spectrum
of nonmotor symptoms. Often physiotherapy is used as an
additional therapy [6], but even though it has been shown
to be effective [7, 8], benefits tend to disappear as soon as
the treatment is over [9] and there is no clear evidence of its
efficacy on nonmotor symptoms.
Thus, as PD progresses, the increasing difficulties in
its management may lead to social isolation as patients
start to feel embarrassed by the disease, with a consequent
deterioration in their quality of life (QoL; [10]). That said,
there is a gap between the effects of the best available medical
treatment and patients’ expectations. In some instances, a
paradoxical discrepancy between an objectively good control
of motor disturbances and an increasing negative feeling of
well-being reported by patients may occur.
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Given that PD has worldwide prevalence of approxi-
mately 10 million people and that this number is expected
to double by 2050 because of increasing longevity [11],
management and treatment of this disease will be a very
important public health problem. Accordingly, the demand
for the development of appropriate complementary strategies
aimed at improving personal and social life of patients and
caregivers is rapidly increasing. Activities such as tai chi [12],
dancing tango [13], and Irish dance [14] have been shown
to produce positive effects mainly on balance and frequency
of falls. However, improvements in nonmotor cognitive and
affective symptoms were absent or very limited. An exception
is given in a study [15] that demonstrated that 3 months
of active music therapy improved both motor abilities and
the emotional status of PD patients. Nevertheless, these
effects disappeared 2 months after the end of therapy. Some
preliminary evidence indicates that group psychotherapy
[16] and occupational therapies [17, 18] might be a useful
treatment for emotional disorders such as depression and/or
anxiety, but samples are usually very small, measurements are
too few, and control groups are not always present.Therefore,
more systematic research is necessary to quantify the effects
of those approaches.
Recently, we have shown that active theatre, in which
patients are directly involved in the representations, is a
valid add-on therapeutic intervention for PD [19]. Com-
pared to patients undergoing physiotherapy, only PD patients
performing theatre had progressive improvements in most
nonmotor clinical scales (especially those tapping into the
affective domains) and, to a lesser extent, in those assessing
motor symptoms. In particular, patients performing theatre
showed remarkable improvements in their level of depres-
sion, in their self-esteem, and in the quality of sleep. However,
most of these beneficial effects emerged only after a training
of 3 years and this evidence casts doubts on the transferability
of the theatre therapy program. In addition, our sample was
relatively small (20 subjects). Finally, as only five clinical
scales were used, they might not be enough to fully appre-
ciate the effects of the interventions. The present study was
designed to both (i) replicate and extend our previous results,
by collecting data on more clinical and neuropsychological
scales, and (ii) develop a form of theatre therapy which would
speed up the emergence of benefits in order to improve its
transferability. Because in the previous study PD patients
showed a significant improvement in most of clinical scales
evaluating the emotional sphere, we hypothesized that a way
to make theatre training more efficient would have been to
train patients to represent emotional events on the stage. The
effects of such “emotional” theatre were compared with those
induced by physiotherapy in other groups of PD patients.
2. Materials and Methods
2.1. Study Participants. Forty-five patients were recruited
from the outpatients of several hospitals in Rome (𝑛 =
25) and from IRCCS Neuromed Hospital, Italy (𝑛 = 20),
by means of referrals from neurologists and of advertising
through local PD associations. Eligibility criteria for includ-
ing PD patients were (i) a diagnosis of idiopathic PD with a
moderate disease severity (Hoehn-Yahr stage 2-3), (ii) a stable
treatment with levodopa (L-dopa) and dopamine agonists,
(iii) absence of cognitive impairment (MMSE score≥ 24), (iv)
absence of severe sensory deficits, (v) absence of severemotor
disability so that they could stand and walk unaided, and (vi)
not being involved in other rehabilitation studies.
We allowed patients recruited from Rome hospitals to be
assigned to the theatre rehabilitation program (theatre group),
while patients fromNeuromedHospital were allowed to enter
in the physiotherapy rehabilitation therapy (control group).
Two main motivations produced this choice: (1) actors were
only available in Rome; (2) the two groups of patients would
not be in contact (Neuromed Hospital is about 200 km from
Rome), avoiding possible complaints about being assigned to
a given group.
After the initial screening, patients who met inclusion
criteria underwent a one-to-one interview (sometimes by
telephone) led by one member of the staff who explained the
type of study in which they were taking part. Ten patients
refused to participate in the theatre group and five in the
physiotherapy group. Motivations were mainly related to the
programmed length of the study or to logistic problems. Of
the remaining 30 patients, six (three from each group) did
not conclude the study because (a) two moved to another
town; (b) three experienced physical problems; and (c) one
had lack of motivation (1). We ended up having 24 patients,
12 per group, who took part in more than 75% of the study
sessions. Throughout the entire course of the study, patients
were allowed to continue taking their dopaminergic therapy,
which was optimized whenever necessary according to the
patient’s needs.The use of antidepressant and hypnotic agents
was equally distributed between the two groups during the
entire course of the study.
All subjects gave their informed consent and were free to
withdraw from the study at any time. The procedures were
approved by the local Institutional Ethics Committee and
were in accordance with the ethical standards laid down in
the Declaration of Helsinki of 1964.
2.2. Clinical Assessment. All patients underwent a clinical
evaluation at the beginning (𝑇0) of the training period and
after 15 months (𝑇1). A neurologist and a psychologist,
blinded to the study groups, evaluated PD patients on clinical
and neuropsychological scales, respectively. We employed
eight clinical scales: (i) theUnified Parkinson’s Disease Rating
Scale (UPDRS), which rates patients’ mood and cognition
(UPDRS I), activities of daily living (UPDRS II),motor symp-
toms (UPDRS III), and complications of therapy (UPDRS
IV); (ii) the Gait and Falls Questionnaire, which measures
gait disturbances; (iii) the Parkinson’s Disease Quality of Life
Scale (PDQ39), which measures the QoL by summing the
scores of its eight subscales (mobility, activities of daily living,
emotionalwell-being, stigma, social support, cognition, com-
munication, and bodily discomfort); (iv) the Beck Depres-
sion Inventory, which measures the level of depression; (v)
the Apathy Evaluation Scale, which measures the level of
apathy (lack of feelings, emotions, interests, or concerns);
(vi) the Hamilton Anxiety Rating Scale, which measures the
level of anxiety; (vii) the Parkinson’s Disease Sleep Scale
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(PDSS), which measures sleep and nocturnal disability in
PD; and (viii) the Schwab and England Scale, which assesses
the degree of functional independence in daily living. In
addition, we assessed some cognitive functions exploiting five
neuropsychological tests: (i) the Raven test, which measures
general intelligence; (ii) the Stroop test, which measures
attention and/or inhibitory functions; (iii) the Rey test, which
measures verbal memory; (iv) the digit span task, which
measures working memory’s capacity for numbers; and (v)
the phonological fluency test, which measures the ability of
participants to generate words that begin with a given letter.
The rating of all scales was carried out in their best ON
medication state calculated after the firstmorning dosewhich
normally allowed the patient to attain the best control of
symptoms. As a result, patients were rated 45–60 minutes
after the administration of an L-dopa dose ranging from 100
to 200mg.
2.3. Emotional Theatre Workshop. The theatrical workshop
consisted of 3-hour daily session, once a week, giving a total
of ∼12 h/month for 15 months. Each session was led by two
professionals, an actor and in turn a dancer or a singer.
Approximately 50 minutes were spent performing either
movement or voice training, while the following 50 minutes
were spent in theatrical training (see Table 1 and Movies 1
and 2 in Supplementary Material available online at https://
doi.org/10.1155/2017/7436725). All exercises were organized
according to a theme (e.g., the experience and expression of
anger). All the remaining time (∼80 minutes) was focused
on performing theatre scenes or theatrical tasks that required
the representation of the chosen theme. The whole program
was divided into three phases: (i) welcome, self-confidence,
and group foundation (∼4 months); (ii) emotional stress
work focusing on six different emotional moods: anger, fear,
happiness, sadness, surprise, and sensuality (∼8 months);
and (iii) free organization, interpretation, and representation
of emotional states by each patient using either texts or
improvisations and/or body movements (∼3 months).
2.4. Physiotherapy. Physiotherapy consisted of 1.5-hour
group sessions, 2 days a week, giving a total of ∼12 h/month
for 15 months. Each session was led by a physiotherapist.
The physical therapy program was designed to increase
strength, power, endurance, and aerobic capacity and to
improve motor functions, postural control, balance, and
gait according to the European Physiotherapy Guideline for
Parkinson’s Disease (for more details, see Table 2).
2.5. Statistics. Using the Shapiro-Wilk test, we verified that,
in the vast majority of instances, the assumption of normality
was verified (108/112 or 96.4%; see Table 3), with the exception
of data recorded with the Schwab and England Scale. Thus,
in the latter case, we used the Wilcoxon signed-rank test for
comparisons within a group and the Mann–Whitney U test
for comparisons between groups, lowering the alpha value
according to the number of comparisons (alpha: 0.05/4 =
0.0125). For all the other scales, a two-way mixed-design
ANOVA [between-subjects factor: GROUP (theatre; con-
trols); within-subjects factor: TIME (𝑇0, 𝑇1)] was employed
for assessing changes in the scores across the experimental
conditions. Bonferroni corrections were applied to all post
hoc tests (pairwise comparisons). In order to provide a mea-
sure of the “effect size,” we computed the partial eta-squared
(𝜂𝑝
2) for each ANOVA, with values of 0.139, 0.058, and 0.01
indicating large, medium, and small effects, respectively, and
Cohen’s d as the effect size for t-tests, with values of 0.2, 0.5,
and 0.8 indicating large, medium, and small effects [20]. As
𝜂𝑝
2 and Cohen’s d allow comparison between the effects of a
given manipulation regardless of other factors that have been
manipulated, they allow comparison of our results with those
of future studies.
3. Results
As shown in Table 4, at time 𝑇0, demographical and clinical
data did not differ between the two groups. The levels of
instruction were similar, preventing a possible criticism that
people from a great metropolis, such as Rome, may be more
educated than those coming from more rural areas.
A two-way mixed-design ANOVA on the amount of L-
dopa equivalent daily dose (LEDD) (mg) administered did
not show a main effect of group (𝑀diff = 117; SD = 123)
(𝐹(1, 22) = 0.91; p = 0.35; 𝜂𝑝2 = 0.04; 95% CI [−137; 373])
or a main effect of time (𝑀diff = 15; SD = 39) (𝐹(1, 22)
= 0.15; p = 0.69; 𝜂𝑝2 = 0.07; 95% CI [−65; 95]) or an
interaction (𝐹(1, 22) = 2.22; 𝑝 = 0.15; 𝜂𝑝
2 = 0.09). However,
theatre-group patients on average had a small decrease in
dopaminergic drug therapy during the course of the study
(LEDD = 34.1mg), while control patients needed on average
an increase in dopaminergic drug therapy (LEDD= 73.8mg).
All the other effects of theatrical training are reported
in Tables 5, 6, and 7. None of the clinical scales measuring
motor symptoms (UPDRS III, GFQ, and PDQ39-mobility),
daily activities (UPDRS II, Schwab and England Scale (The
Wilcoxon signed-rank test did not show any significant
difference between 𝑇0 and 𝑇1 either in theatre patients (p =
0.65) or in controls (p = 1). The Mann–Whitney U test did
not show differences between theatre patients and controls
either at 𝑇0 (p = 0.89) or at 𝑇1 (p = 0.55).), and PDQ39-
activities of daily living), or physical problems (UPDRS IV
and PDQ39-bodily discomfort) showed significant differ-
ences either within or between the two groups. The same
applied to cognitive functionsmeasured either by theUPDRS
I or by the neuropsychological tests, with the exception of
the reading time of the Stroop test. Here, the main effect of
time indicates that, overall, patients increased the speed of
reading over the 15 months. This effect was qualified by the
interaction group ∗ time, which showed that only theatre
patients improved their reading time (Tables 5, 6, and 7 and
Figure 1).
While motor symptoms and cognitive functions were not
affected by either treatment, four scales addressing the emo-
tional/affective domains, that is, those measuring depression,
apathy, stigma, and emotional well-being, showed significant
improvements from 𝑇0 to 𝑇1 in the theatre group but not
in the control group (Tables 5, 6, and 7 and Figure 1).
In all these cases, the main effect of the factor time was
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Table 1: Exercises included in a typical emotional theatre training session. It must be remarked that some but not all exercises were performed
in each session.
Movement training
Proprioception Visualization; self-awareness; breath exercises; postural exercises
Basic motor skills practice
Breathing exercises; spinal column exercises; head exercises; limb exercises; foot exercises;
hand exercises; muscle exercises; joint exercises; stretching; strength and flexibility;
coordination; dissociation; active/passive motion; balance; memory; sequences; meaningful
actions; nonfunctional, expressive movement
Space Body space; personal space; proximal space; medial and distal space; imaging space; spatialcues
Time Internal time; external time; temporal cues; rhythm
Relationship Sound; solo work; couple work; group work; contact
Voice training
Proprioception Visualization; self-awareness; postural exercises
Basic motor skills practice Spinal column exercises; head/neck exercises; limb exercises; foot exercises; hand exercises;pelvic exercises; shoulder exercises
Breathing
Diaphragmatic breathing; movements of abdominal muscles; pelvis exercises; emission of
breath for increasing time/with puffs; vocal emission of the consonant “S,” “SH,” and “TS” for
increasing time/with puffs
Resonators Vocal emission of the “M” consonant, with closed mouth and rhythmic movements, from lowto high pitches
Vowels emission Individual emission of vowels following different orders with a single breath, from low to highpitches, from low to high volume
Articulation Mouth and tongue exercises; facial muscles exercises; articulation of single consonants;exasperated articulations of words; rhythmic articulation of lyrics
Musicianship Performing scales and arpeggios with different syllables/with two-syllable words from low tohigh pitches in different rhythms, from low to high volume
Singing Improvisation (solo work, couple work, and choral work); learning and performing a song(choral work)
Theatre training
Vocal technique Breathing; diaphragmatic breathing; vocal exercise; articulation of consonant; syllables andword exercises; increasing and decreasing voice
Improvisation and
experimentation
Improvisation linked on a given idea; timing and rhythm; variations about the story; including
all the partners on stage in a common happening; self-collocate in a drama; fixing the acme;
exit the situation; totally enter again in the drama; use of the text; apperceive a personal feeling;
communicate it to audience; use of the stage like a chessboard; any step is an emotional stage;
Performing with one, two, or three partners; create a story, interpreting and closing it with a
comic end. Control and experience the emotional states associated with the story and, finally,
reinterpret it with expressing the opposite emotion; exercises of theatrical strategies to be
useful for partners; increase and decrease scenic rhythms; deconstruction of a drama, linked to
bodily and vocal reps; positive training to prepare to facing audience
Dramaturgy
Comedy of Arts techniques; techniques of pantomime; use of the body to create a feature; kind
of walking to fix it; study of classic text; dramaturgical analysis; methods to memorize the
learned techniques of the Comedy of Arts
explained by the interaction group ∗ time, which showed a
significant improvement in theatre patients and no changes
in the controls over the period of treatment. The levels of
anxiety and the social support (PDQ39-social support) had
a very similar tendency, but the decrease in anxiety in the
theatre group did not reach significance. In addition, the
theatre training led to an improvement in the quality of sleep
(PDSS), the cognitionmeasured by the subscale of the PDQ39
and, more marginally, the ability to communicate (PDQ39-
communication).
4. Discussion
The present study successfully replicates our previous results
by confirming the efficacy of theatre therapy as an add-on
rehabilitative tool for PD patients [19]. The novel finding is
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Table 2: Exercises included in the physiotherapy rehabilitation program. Depending on the single patient’s motor and functional status, the
physiotherapist could include exercises other than those indicated as basic exercises.
Activities Basic exercises
Supine position (15 minutes)
Diaphragmatic, segmental, and deep breathing exercises; movements to the fullest range of
motion of hip, knee, ankle, shoulder, elbow, and wrist; postural changes to lateral and prone
position
Seated position (15 minutes) Muscle-stretching of scapular, hip flexor, hamstring, and gastrocnemius; active flexion,extensions, and rotation of upper and lower limbs
Standing position (15
minutes)
Standing wall push-up; pelvic mobility (anterior and posterior tilts); side to side tilts; pelvic
clock exercise and ball exercise to facilitate sitting control; sit to stand transfer
Overground gait training
(20 minutes) Overground gait training (forwards, backwards, and lateral); walking on the spot
Balance training (15
minutes) Weight shifts in both sitting and standing; sitting and standing activities on gymnastic ball
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Figure 1: Mean scores and standard error of the means at the two time points for the theatre (gray bars) and control group (black bars) in the
scales or subscales showing a significant effect at the mixed-design ANOVAs (see text and Table 5 for more details). Bars indicate significant
differences after post hoc analyses, the single∗ indicates values of𝑝 < 0.01, and the double∗ indicates values of𝑝 < 0.001. PDQ39: Parkinson’s
Disease Quality of Life Scale; PDSS: Parkinson’s Disease Sleep Scale.
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Table 3: 𝑝 values obtained from the Shapiro-Wilk test of normality
for the two groups of PD patients (theatre group and control group)
in all clinical scales and subscales at the beginning (𝑇0) and the end
(𝑇1) of the rehabilitation treatments. 𝑝 values less than 0.05 indicate
that the data are not from a normally distributed population and are
indicated in bold. UPDRS:Unified Parkinson’s Disease Rating Scale;
GFQ: Gait and Falls Questionnaire; PDQ39: Parkinson’s Disease
Quality of Life Scale; PDSS: Parkinson’s Disease Sleep Scale.
Theatre Controls
𝑇0 𝑇1 𝑇0 𝑇1
UPDRS I 0.147 0.563 0.109 0.370
UPDRS II 0.18 0.38 0.579 0.047
UPDRS III 0.666 0.638 0.596 0.375
UPDRS IV 0.303 0.091 0.175 0.762
Schwab and England Scale 0.020 0.012 0.051 0.004
GFQ 0.148 0.302 0.599 0.684
PDQ39 (total score) 0.240 0.542 0.062 0.784
PDQ39 (mobility) 0.834 0.526 0.247 0.667
PDQ39 (activities of daily living) 0.559 0.703 0.733 0.088
PDQ39 (Emotional well-being) 0.303 0.956 0.137 0.825
PDQ39 (stigma) 0.133 0.008 0.071 0.412
PDQ39 (social support) 0.144 0.083 0.333 0.598
PDQ39 (cognition) 0.201 0.109 0.143 0.135
PDQ39 (communication) 0.071 0.095 0.135 0.174
PDQ39 (bodily discomfort) 0.745 0.360 0.916 0.813
Beck Depression Inventory 0.126 0.324 0.103 0.013
Apathy Evaluation Scale 0.252 0.291 0.071 0.144
Hamilton Anxiety Rating Scale 0.338 0.286 0.440 0.366
PDSS 0.702 0.341 0.343 0.479
Raven test 0.099 0.051 0.623 0.256
Stroop (word reading time) 0.448 0.659 0.393 0.189
Stroop (color reading time) 0.080 0.262 0.542 0.025
Stroop (interference reading time) 0.321 0.080 0.278 0.365
Rey immediate recall 0.778 0.757 0.128 0.088
Rey delayed recall 0.551 0.923 0.086 0.062
Forward digit span 0.197 0.543 0.432 0.354
Backward digit span 0.069 0.123 0.433 0.187
Phonological fluency test 0.382 0.216 0.450 0.416
that theatre training based on the representation of emotions
speeds up the appearance of benefits in the affective domain.
We will discuss why theatre might represent a very effective
form of cognitive rehabilitation.
4.1. Why Is Theatre Training Effective? Even though motor
disturbances are mandatory to make the diagnosis of PD,
there is now a consensus around the idea that this is not a
pure motor disorder but a multifaceted one. Several factors
contribute to its severity. Nonmotor symptoms have been
shown to play amore important role thanmotor symptoms in
reducing the health-related and perceivedQoL in PD [21, 22].
In particular, depression seems to deeply affect the feelings
about the disease perception and its future consequences
[21, 23].
Recent findings have started to shed light on the link
between the depletion of dopaminergic neurons occurring in
PD and the genesis of neuropsychiatric nonmotor symptoms.
Thedisruption of the dopaminergic system seems to affect the
decision-making processes underlying the genesis of motor
acts (see [24]) because of a wrong evaluation of the costs
of movements [25, 26], making this cost too high [26]. The
wrong value assignment decreases the motivation to act,
inducing either bradykinesia or akinesia and even apathy.
Other evidence indicates that, in healthy subjects, L-dopa not
only plays a role during decision-making under risky choices
but also has a critical role in generating a subjective feeling of
happiness which follows the receipt of reward [27].Therefore,
the loss of dopamine is likely to affect both the planning of
actions and the pleasant feelings normally associated with
rewarding events possibly leading to anhedonia, a core symp-
tom of major depression. Overall, it is not surprising that an
objectively good control of motor symptoms might not be
coupled with a positive feeling of well-being experienced by
patients. This evidence has prompted the need for develop-
ing auxiliary approaches to medical therapy. However, the
effectiveness of these approaches had rarely been explored
with proper randomized controlled trials (for a review, see
[28, 29]). Most studies suffer from having small and/or
heterogeneous samples, and sometimes methodologies are
not rigorous enough (see [12] for a remarkable exception).
In addition, the effects of most interventions do not last
more than a few months, a span of time that is very likely
too short to promote the so-called brain plasticity, that is,
the neural mechanism underlying behavioral changes (e.g.,
[30, 31]). Moreover, another factor has to be considered to
evaluate the effectiveness of a therapy, that is, the different
degrees to which it affects motor, emotional, and inter-
personal components. For instance, art therapies based on
drawing, painting, sculpting, or music playing allow patients
to express themselves spontaneously, but they tend to lack the
intersubjective interactions normally occurring in real life,
and their impact on body motor control is rather limited.
Dance and martial arts require physical involvement but
they do not reproduce the intersubjective interactions of real
life. The opposite holds true for occupational therapies. In
contrast, theatre training allows a more holistic approach
as, to successfully impersonate a character, an actor needs
to control his body, reproduce the character’s emotions and
way of thinking, and identify himself with his social role.
To some extent, an actor needs to learn a way to become
another person on the stage and to behave accordingly. This
is potentially a successful exercise through which PD patients
could develop new strategies for carefully controlling their
bodies and minds within a protected environment, that is, in
a place where they do not feel judged by others. In addition,
both during and outside the performance, patients have to
continuously interact and thus they are forced to socialize.
These unique features make theatre an ideal playground for
deeply motivating patients, allowing them to reacquire the
control of their social, psychological, and emotional life and
to transfer these abilities to everyday life situations.
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Table 5: Mean scores and standard deviations obtained by the two groups of PD patients (theatre group and control group) in all clinical
scales and subscales at the beginning (𝑇0) and the end (𝑇1) of the rehabilitation treatments.
Theatre Controls
𝑇0 𝑇1 𝑇0 𝑇1
UPDRS I 2.9 ± 1.9 3 ± 1.9 2.8 ± 1.7 3.1 ± 1.4
UPDRS II 8.1 ± 4.9 7.8 ± 4.9 6.6 ± 3.8 7.6 ± 4.9
UPDRS III 21.4 ± 9.3 24.2 ± 9.9 21.2 ± 5 22 ± 4.9
UPDRS IV 4.4 ± 3.9 3.2 ± 3.2 3.9 ± 2.2 4.1 ± 1.7
Schwab and England Scale 90 ± 7.4 89.2 ± 6.7 90 ± 9.5 90 ± 10.4
GFQ 20.1 ± 15.8 20.7 ± 15.7 10.5 ± 6.2 10.9 ± 6.4
PDQ39 (total score) 58.1 ± 27.1 50.3 ± 22.6 47.3 ± 14 52.2 ± 16.9
PDQ39 (mobility) 15.4 ± 9.2 16.8 ± 9.3 12.8 ± 5.7 15.8 ± 5.5
PDQ39 (activities of daily living) 9.3 ± 5.3 9.1 ± 4.1 8 ± 2.9 9.7 ± 4.2
PDQ39 (Emotional well-being) 11 ± 5.5 8.2 ± 4.9 11.1 ± 3.6 10.9 ± 3.3
PDQ39 (stigma) 6.8 ± 3.9 3.5 ± 3.3 3 ± 1.8 3.4 ± 1.7
PDQ39 (social support) 2.4 ± 2.1 1.9 ± 1.4 1.9 ± 1.4 1.9 ± 1.1
PDQ39 (cognition) 4.6 ± 3.7 3 ± 2.8 2.9 ± 1.5 3 ± 1.5
PDQ39 (communication) 2.5 ± 2.3 1.9 ± 1.6 2.1 ± 1.6 2.5 ± 1.3
PDQ39 (bodily discomfort) 6.1 ± 2.1 5.9 ± 2.4 5.5 ± 2 5 ± 2.1
Beck Depression Inventory 11.4 ± 5.9 7 ± 5 10.3 ± 5.2 10.4 ± 5.3
Apathy Evaluation Scale 14.9 ± 5.6 10.1 ± 5.3 12.8 ± 6.1 13.7 ± 6.2
Hamilton Anxiety Rating Scale 13.4 ± 5.6 10.2 ± 6.1 13.8 ± 7.2 14.3 ± 6.8
PDSS 20.1 ± 11.1 15.8 ± 9.5 13.9 ± 5.4 14.7 ± 4.3
Raven test 29.1 ± 5.1 29.4 ± 5.5 28.9 ± 3.8 29.2 ± 3.1
Stroop (word reading time) 15.8 ± 1.7 13.5 ± 1.9 14.3 ± 1.9 14.8 ± 2.2
Stroop (color reading time) 22.3 ± 4.4 21.3 ± 4.6 19.8 ± 3 20 ± 2.7
Stroop (interference reading time) 39.5 ± 10.6 38.5 ± 11.8 42.8 ± 8 43.2 ± 6.8
Rey immediate recall 47.8 ± 8.4 48.4 ± 9.3 43.3 ± 9.3 43.9 ± 7.3
Rey delayed recall 9.3 ± 2.2 9.5 ± 2.5 9.3 ± 3 9.8 ± 2.6
Forward digit span 6.8 ± 1.5 6.9 ± 1.6 6.9 ± 1.2 7 ± 1.3
Backward digit span 4.3 ± 1.1 4.2 ± 0.9 4.1 ± 1.2 4.5 ± 1
Phonological fluency test 45.3 ± 15.4 46.1 ± 13.4 38.2 ± 9.8 39 ± 9.1
4.2. The Effectiveness of Emotional Theatre. A novel finding
of the current work is that the emotional theatre training
boosts the improvements in the emotional sphere, allowing
the emergence of significant ameliorations in more clinical
scales tapping the affective domain than in our previous study
[19]. After 15 months, there were no improvements in any of
the clinical scales measuring either motor symptoms, daily
activities, or physical problems. Nevertheless, even though
patients still suffered fromphysical discomforts, their feelings
about the disease and about its evolution were so positive that
they declared they could not stop their theatrical activities
(Movies 3 and 4). The improvements in the quality of sleep
are likely to be associated with the increased psychological
well-being. This is in keeping with the idea that improve-
ments in mood bring about an improved perception of the
disease [21, 22, 32]. It must be remarked that performing
this type of theatre training is not an enjoyable activity by
definition. Patients experienced some form of distress when
playing emotionally negative events (e.g., the feeling of being
powerless in front of someone else; seeMovie 2), and some of
them reexperienced, directly or indirectly, painful situations
(e.g., the loss of some beloved person). Therefore, our results
could not be simply explained by the fact that patients
were attending an enjoyable social activity: the training was
a complex pathway into an emotional world, leading the
patients to regain the ability to manage their emotions much
better than patients who were having physiotherapy (i.e., the
most common treatment associated with medical therapy).
In our opinion, these elements could explain the different
outcomes of other types of complementary therapies, for
example, dance [13, 14] or martial arts [12].
4.3. Limitations of the Study. We are aware of some method-
ological limitations of our study. First, this is not a random-
ized study and in Materials and Methods we have explained
why we exploited this experimental design. However, we
measured several clinical parameters (diagnosis, age, years
of disease, onset of disease, education, H&Y, LEDD, and
MMSE) and we demonstrated that they were not different
across theatre and control groups. In addition, the two groups
were scored by blind raters, thus avoiding bias during the
evaluations. Obviously, as in similar studies, it was impossible
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Table 6: Results of the two-way mixed-design ANOVA with GROUP (theatre; controls) as between subjects’ factor and TIME (𝑇0, 𝑇1) as
within subjects’ factor, comparing scores of clinical scales (or subscales, top part of the table) and of neuropsychological tests (lower part of
the table). Asterisk (∗) indicates subscales of Parkinson’s Disease Quality of Life Scale (PDQ39). 𝜂𝑝
2 represents the partial eta-squared; values
higher than 0.14 indicate strong effect sizes (see Section 2.5 for further details). 𝑝 values less than 0.05 as well as the corresponding 𝐹 and 𝜂𝑝
2
values are indicated in bold. Unified UPDRS: Parkinson’s Disease Rating Scale; GFQ: Gait and Falls Questionnaire; PDSS: Parkinson’s Disease
Sleep Scale; TR: time for reading words; TC: time for naming color; TI: time for naming color during interference.
TIME GROUP TIME × GROUP
𝐹(1, 22) p value 𝜂𝑝2 𝐹(1, 22) p value 𝜂𝑝2 𝐹(1, 22) p value 𝜂𝑝2
UPDRS I 0.83 0.37 0.04 0.004 0.95 <0.001 0.29 0.59 0.01
UPDRS II 0.26 0.62 0.01 0.22 0.64 0.01 1.03 0.32 0.04
UPDRS III 1.55 0.23 0.07 0.19 0.67 0.01 0.44 0.51 0.02
UPDRS IV 1.16 0.29 0.05 0.04 0.85 0.002 1.98 0.17 0.08
GFQ 0.26 0.62 0.01 4.06 0.06 0.16 0.01 0.93 <0.001
PDQ39 0.47 0.49 0.02 0.26 0.61 0.01 3.92 0.06 0.15
Mobility∗ 3.09 0.09 0.12 0.41 0.53 0.02 0.37 0.55 0.02
Activities of daily living∗ 0.57 0.46 0.02 0.06 0.81 0.003 0.86 0.36 0.04
Emotional well-being∗ 5.4 0.03 0.19 0.71 0.41 0.03 4.2 0.05 0.16
Stigma∗ 14.1 0.001 0.39 3.24 0.08 0.13 23.3 <0.001 0.51
Social support∗ 1.44 0.24 0.61 0.12 0.73 0.005 2.82 0.11 0.11
Cognition∗ 5.13 0.03 0.19 0.72 0.41 0.03 6.3 0.02 0.22
Communication∗ 0.14 0.71 0.006 0.01 0.9 0.001 5.11 0.03 0.19
Bodily discomfort∗ 1.26 0.27 0.05 0.82 0.38 0.04 0.31 0.58 0.01
Beck Depression Inventory 29.6 <0.001 0.57 0.27 0.6 0.12 34.4 <0.001 0.61
Apathy Evaluation Scale 8.78 0.007 0.28 0.09 0.76 0.004 18.93 <0.001 0.46
Hamilton Anxiety Rating Scale 1.47 0.24 0.06 0.85 0.37 0.04 2.73 0.11 0.11
PDSS 4.34 0.049 0.16 0.13 0.27 0.06 8.7 0.007 0.28
Raven test 0.65 0.43 0.03 0.13 0.91 0.001 0.13 0.9 0.001
Stroop test (TR) 6.81 0.016 0.24 0.14 0.91 0.001 14.4 0.001 0.4
Stroop test (TC) 0.82 0.37 0.04 1.59 0.22 0.07 2.28 0.14 0.09
Stroop test (TI) 0.06 0.81 0.003 1.15 0.29 0.05 0.35 0.56 0.016
Rey test (immediate recall) 0.24 0.63 0.01 1.84 0.19 0.08 <0.001 1 <0.001
Rey test (delayed recall) 0.94 0.34 0.04 0.04 0.84 0.002 0.1 0.75 0.005
Digit span test (forward) 0.08 0.77 0.004 0.03 0.87 0.001 <0.001 1 <0.001
Digit span test (backward) 0.37 0.55 0.02 0.07 0.8 0.003 0.83 0.37 0.04
Phonological fluency test 0.6 0.44 0.03 2.12 0.16 0.09 <0.001 1 <0.001
Table 7: Post hoc analyses of significant interactions obtained in two-waymixed-designANOVAs [between subjects’ factor: GROUP (theatre;
controls); within subjects’ factor: TIME (𝑇0, 𝑇1), see Table 5]. Data are reported just for those post hoc tests which survived the Bonferroni
correction. Asterisk (∗) indicates subscales of Parkinson’s Disease Quality of Life Scale.𝑀diff : differences between the means; SDdiff : standard
deviation of𝑀diff , CIdiff : confidence interval of𝑀diff . Other abbreviations are as in Table 6.
Theatre 𝑇0 versus theatre 𝑇1 Theatre 𝑇0 versus controls 𝑇0
𝑀diff SDdiff CIdiff Cohen’s 𝑑 p value 𝑀diff SDdiff CIdiff Cohen’s 𝑑 p value
Emotional well-being∗ 2.8 0.9 [0.9, 4.7] 0.72 0.005 — — — — —
Stigma∗ 3.3 0.5 [2.2, 4.5] 1.2 <0.001 3.8 1.2 [1.3, 6.4] 1.5 0.005
Cognition∗ 1.6 0.5 [0.6, 2.5] 0.63 0.003 — — — — —
Beck Depression Inventory 4.4 0.5 [3.3, 5.6] 1.07 <0.001 — — — — —
Apathy Evaluation Scale 4.8 0.9 [2.9, 6.8] 1.18 <0.001 — — — — —
PDSS 4.3 1.2 [1.8, 6.8] 0.55 0.002 — — — — —
Stroop test (TR) 2.2 0.5 [1.2, 3.3] 1.71 <0.001 — — — — —
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to make patients blind to the treatment condition. Overall,
we believe that the limitation of this experimental approach
is more theoretical than practical, as it must be supposed
that unpredictable and hidden factors systematically affected
a certain group.
Second, our sample is relatively small (but similar to
those of most studies in this field (e.g., [13–15])). To address
this problem, we performed very stringent statistical analyses
providing parameters that allow estimation of the effect size
and facilitate the interpretation of the substantive as well as
the statistical significance of the results [20]. In all instances,
we had strong or very strong effect sizes, indicating the
consistency of our findings.
Third, we had a relatively high drop-out rate, mainly at
the recruitment stage, whichwas principally due to the length
of the treatment. Patients at the beginning of the study were
requested to give their availability for 15 months, that is, a
very long period of time especially for people affected by a
neurodegenerative disorder. Indeed,we are not aware of other
studies able to keep patients for such a long period of time.
Fourth, as in the previous study, we included patients with
a moderate form of PD because they are likely to fully enjoy
the theatrical experience. However, whether this treatment
could also be effective on patients with more severe forms of
PD, maybe implementing a virtual reality training (e.g., [33])
for those who could not walk, needs to be tested.
Fifth, as clinical scales are self-reported measures, they
require the conscious participation of the person, which can
alter the final outcomes. Thus, there is a need to collect
data such as psychophysiologicalmeasurementswhich can be
used tomonitor the emotional state of patients independently
of their conscious reporting to assess how theatre training
changes the processing of affective states of PD patients
during the therapy.
5. Conclusions
In conclusion, even though this work suffers from some
weaknesses and must be viewed as a pilot study, it confirms
that theatre represents a valid add-on therapy for PD and it
provides some evidence that emotional training improves the
patients’ mood and thus patients’ QoL.
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